SEN0014196

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
AIM Selisistat (SEN0014196), a first-in-class SirT1 inhibitor, is being developed as a disease-modifying therapy for Huntington's… Expand
Is this relevant?
2012
2012
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat… Expand
Is this relevant?
2012
2012
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selisistat… Expand
Is this relevant?
2012
2012
To date no disease modifying therapy has shown efficacy in Huntington9s Disease (HD). The PADDINGTON (Pharmacodynamic Approaches… Expand
Is this relevant?
2012
2012
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat… Expand
Is this relevant?